Welcome to our dedicated page for Biote news (Ticker: BTMD), a resource for investors and traders seeking the latest updates and insights on Biote stock.
Biote Corp (BTMD) delivers innovative hormone optimization solutions through its certified practitioner network. This news hub provides investors and healthcare professionals with timely updates on the company's strategic initiatives in personalized medicine and practice-building technologies.
Access authoritative coverage of Biote's latest developments including regulatory milestones, partnership announcements, and certification program expansions. Our curated news collection helps stakeholders track the company's progress in standardizing hormone therapy protocols while supporting medical practices.
Key updates include earnings reports detailing Biote's practice-building platform growth, analysis of new training modules for practitioners, and coverage of clinical advancements in personalized hormone treatments. Bookmark this page for streamlined access to operational updates and market positioning insights.
Biote (Nasdaq: BTMD), a provider of preventive health care solutions specializing in personalized hormone optimization and therapeutic wellness, has announced its upcoming first quarter 2025 financial results release. The company will present its results on Wednesday, May 7, 2025, after market close, followed by a conference call at 5:00 p.m. ET.
Investors can access the conference call via U.S. toll-free number (844) 481-2820 or International number (412) 317-0679. A webcast replay will be available on the company's Investor Relations website Events page after the call concludes.
Biote Corp (NASDAQ: BTMD) announced significant insider stock purchases, with several Board of Directors members and CEO Bret Christensen collectively acquiring approximately 260,000 shares through open market transactions.
Executive Chairman Marc Beer expressed confidence in the company's business strategy and long-term outlook, specifically highlighting CEO Christensen's capabilities to implement decisive changes for business growth. Beer emphasized Christensen's extensive background in diagnostic, therapeutic, and medical device healthcare sectors as key qualifications for leading Biote's expansion.
Biote (NASDAQ: BTMD) reported its Q4 and full-year 2024 financial results, showing mixed performance. Full-year revenue increased 6.4% to $197.2 million, with procedure revenue reaching $150.3 million. The company achieved a gross profit margin of 70.5% and net income of $0.05 million.
In Q4 2024, revenue grew 9.0% to $49.8 million, with procedure revenue up 5.0%. However, Q4 net income decreased to $3.5 million ($0.10 per share) from $12.1 million ($0.18 per share) in Q4 2023. The quarter saw a 71.8% gross profit margin and Adjusted EBITDA of $15.1 million.
For fiscal 2025, Biote projects procedure revenue growth of 2-4% and dietary supplements revenue increase of 5-10%. The company plans to focus on maximizing top-tier providers, expanding practitioner network, and strengthening commercial execution.
Biote (Nasdaq: BTMD), a provider of preventive health care solutions specializing in personalized hormone optimization and therapeutic wellness, has scheduled its fourth quarter and full year 2024 financial results announcement for March 12, 2025, after market close.
The company will host a conference call at 5:00 p.m. ET on the same day. Investors can access the call by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (International). A live webcast will be available, and a replay will be posted on the Events page of Biote's Investor Relations website following the call.
AccessHope announces expansion of its executive leadership team with key appointments amid rapid growth. Dr. Yousuf Zafar, a Duke University oncologist and former Optum executive, joins as Chief Medical Officer. Peter Bridges, a veteran digital health leader, becomes Chief Strategy and Growth Officer, while Debra Morris is promoted to President.
The company, which delivers leading-edge cancer expertise, recently completed a spinout from City of Hope and secured $33 million in Series B funding. AccessHope has experienced double-digit annual growth since its founding and expanded its network of partnerships with NCI-Designated Comprehensive Cancer Centers, including prestigious institutions like Dana-Farber Cancer Institute and Johns Hopkins Medicine.
Biote (NASDAQ: BTMD) announced its Q3 2024 financial results. Revenue stood at $51.4 million, a 12.8% increase from the prior year. Procedure revenue was $37.9 million. Gross profit margin improved to 70.5%, driven by vertical integration and cost management. Net income was $12.7 million, with diluted EPS at $0.33, compared to $19.6 million and $0.24 respectively, in Q3 2023. Adjusted EBITDA grew to $16.2 million, with a margin of 31.5%.
Despite temporary disruptions from enhanced clinical decision support software and hurricane-related clinic closures, Biote anticipates procedure revenue growth to reaccelerate in 2025. The company launched proprietary software to bolster its competitive edge. Due to these disruptions, Biote adjusted its 2024 financial guidance to $197-$201 million in revenue and $58-$61 million in Adjusted EBITDA, down from $200-$204 million and $60-$63 million respectively.
Biote (Nasdaq: BTMD) has scheduled its third quarter 2024 financial results announcement for Tuesday, November 12, 2024, after market close. The company, which specializes in preventive health care through personalized hormone optimization and therapeutic wellness, will host a conference call at 5:00 p.m. ET on the same day. Participants can join via U.S toll-free number (844) 481-2820 or International number (412) 317-0679. A webcast replay will be available on the company's Investor Relations website after the event.
Biote (NASDAQ: BTMD) reported its Q2 2024 financial results, highlighting revenue of $49.2 million and a gross profit margin of 68.9%, up from 67.9% last year. Procedure revenue grew by 7.8%, reaching $38.4 million. The company faced a net loss of $(10.5) million, an improvement from a $(13.1) million loss in Q2 2023. Adjusted EBITDA was $12.7 million, down from $14.5 million a year earlier, due to increased sales and marketing investments.
Biote expanded its clinic network by 30% in the first half of 2024 and continued rolling out its BioteRx suite of hormone and wellness therapies, now in approximately 600 clinics. The company settled litigation with its founder, repurchasing 18.4 million shares. Guidance for 2024 remains unchanged, with revenue expected between $200-$204 million and Adjusted EBITDA between $60-$63 million.
Biote Corp. (Nasdaq: BTMD), a leader in preventive health care through personalized hormone optimization and therapeutic wellness, has announced its upcoming second quarter 2024 financial results release. The company will disclose its financial performance on Thursday, August 8, 2024, after market close, followed by a conference call at 5:00 p.m. ET the same day.
Investors and interested parties can access the conference call by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (International). A live webcast of the call will also be available. Following the event, a replay of the webcast will be accessible on the Events page of Biote's Investor Relations website.
Biote (NASDAQ: BTMD) has reached a $60 million agreement with stockholder Marci M. Donovitz to resolve ongoing litigation. The company will repurchase approximately 8.3 million shares and cancel around 4.0 million earnout shares owned by Ms. Donovitz. The repurchases, averaging $7.23 per share, will be executed over a three-year schedule. This settlement aligns with Biote's capital allocation strategy and aims to enhance long-term shareholder value. Biote's management believes this transaction represents an advantageous use of capital, eliminating future earnout obligations and consolidating share control.
